The structures of two remote glucocorticoid responsive units (GRUs) that cooperatively interact to promote celltype specific glucocorticoid induction of rat tyrosine aminotransferase gene expression have been analyzed. DNAase I footprinting and gel mobility shift analyses reveal a complex array of contiguous and overlapping sites for cell type-specific DNA binding proteins. Apart from the glucocorticoid receptor, two liver-specific nuclear factors possess multiple binding sites in each of these GRUs: C/EBP and a newly identified liverspeclflc factor: HNF5. C/EBP possesses four binding sites In each GRU; a DNA-binding protein with similar binding specificity has been identified in fibroblasts; this protein could be related to AP-3. HNF5 possesses two binding sites in one GRU and four in the other. There are also HNF5 binding sites in numerous regulatory regions of other liver-specific genes. The interaction of HNF5 with DNA gives a characteristic DNAase I footprint with hypersensitive sites in the middle of the recognition sequence. Some of the C/EBP and HNF5 binding sites overlap in a conserved arrangement.
INTRODUCTION
The glucocorticoid receptor is a well-characterized transcription factor which, upon binding of the hormone, regulates transcription of its target genes (for reviews see 1, 2). Sequences responsible for glucocorticoid activation of transcription can be located upstream or downstream from the promoter and thus behave as typical enhancers (1, 2) . The general structure of enhancers as well as promoters is modular (3, 4, 5) . They are composed of multiple overlapping binding sites for different transcriptional activator proteins (4, 5) . These discrete basic units of regulatory sequences have been termed enhansons (5) . Functional modules are obtained by different combinations of different, hierarchically distinguishable, types of enhansons (5) .
Glucocorticoid receptor binding sites (GRBS) can combine with numerous transcription factor binding sites to form a glucocorticoid responsive unit (GRU, 6). The diversity of these factors allows a very complex repertoire of GRUs with various regulatory potentials, notably cell type-specificity, to be produced.
The tyrosine aminotransferase (TAT, E.C.2.6.1.5.) gene is expressed specifically in liver where its transcription is increased by glucocorticoids (for a review see 7) . Full glucocorticoid induction of the rat TAT gene is achieved through cooperative interaction of two remote GRUs (8) . One, referred to as HSin, maps around -2,500 (9) ; the other, referred to as HSV, maps around -5,500 (8) . HSin corresponds to a liver-specific glucocorticoid-dependent DNAase I hypersensitive she (8, 9, 10) . In rat hepatoma cells it is not very active by itself and requires the presence of HSV to produce the same level of glucocorticoid stimulation as the endogenous gene (11) . HSin contains three GRBSs, termed GRE 1, 2 and 3, two of them (GRE 2 and 3) being within regions necessary for its activity (9) . In contrast to HSin, HSV corresponds to a constitutive liver-specific DNAase I hypersensitive site; furthermore it is not active in the absence of HSin (11) . It contains a GRBS essential but not sufficient for its activity since flanking sequences are also necessary (11) . We show here that both GRUs have a cell-type specific activity associated with multiple binding sites for two cell-type specific transcription factors.
MATERIALS AND METHODS
Plasmid constructions, cell culture and transfections The construction of most plasmids presented here have been described previously (8) . The HSV fragment in pCR51 has been obtained using the polymerase chain reaction (12) , starting from a fragment (position -5,857 to -5,180) and amplified using the oligonucleotides: GAGCTCGACGAACTGGCCTGTG and AA-GCTTTGTGGCTTTTCTCTC. After self-ligation, the fragment was cleaved with Sst I and Hind IE before cloning between the Sst I and Hind m sites of pKT531 (8) . pGR2 was constructed
• To whom correspondence should be addressed by insertion between the Xba I and the Sal I sites of pUTKat4 (13) of the fragment resulting from the annealing of the two following oligonucleotides: CTAGCTGTACAGGATGTTCTA-GCTAC and TCGAGTAGCTAGAACATCCTGTACAG. The nucleotide sequences of all the in vitro synthesized fragments was verified after cloning by the dideoxy sequencing procedure (14) .
Plasmid preparations, cell culture and transfections using the CaPC>4 precipitation procedure were exactly as described (8) except for mouse L cells which were grown in DMEM plus 8% foetal calf serum and seeded at 2.10 6 cells per 10 cm-diameter plates the day before DNA addition.
Crude nuclear extract preparation, DNAase I footprinting and gel mobility shift experiments Crude nuclear extracts (CNE) were prepared from 10 9 cells grown in plates. The cells were recovered from the plates using trypsin and resuspended in 40 ml of buffer H (0.4 M sucrose, 10% glycerol, lOmM Hepes (pH 7.6), 60mM KC1, 15 mM NaCl, 0.15 mM spermine, 0.5 mM spermidine, lmM EDTA, lmM DTT, 0.1 mM PMSF). The cells were lysed with a mild detergent (NP40) as follows: The cell suspension was diluted in 40 ml of buffer H containing either 0.5% NP40 (H4 II cells) or 0.8% NP40 (L cells). After a 3 min.-incubation at 4 C C the suspension was diluted with 80 ml of buffer H and the nuclei recovered by centrifugation. The pelleted nuclei were further purified on a 2M sucrose cushion (in buffer H) and the CNEs were prepared according to the procedure of Gorski etal. (15) .
DNAase I footprinting was performed exactly as described (16) . Gel shift assays were performed with blunt-end ds oligonucleotides generated by the annealing of two complementary ss synthetic oligonucleotides labeled on each strand using polynucleotide kinase and purified on acrylamide gel. The incubation of 10,000 cpm of the labeled oligonucleotide with the CNE was carried out in the same conditions as for DNAase I footprinting for 15 min. at 4 C C. Gel (8% acrylamide) conditions were as described (17) . The sequences of the oligonucleotides, named as in the figures, are: -si: 5' AAGCCC AAGGTTTACAATCTCTGC 3'; -s2: 5' TACTTTATTTGCA ATAGAAAATC 3'; -s3: 5' CTGAAAGTTTCCCCATGTCC AACA 3'; -s4: 5' CTAGAACAAACAAGTCCTGCGT 3'; -s4 mut: 5' CTAGAAAAAACCAGTCCTGCGT 3' (mutated positions underlined); -s5: 5'CGCCTGTCGGTTTCTGGGTG TGGTGG 3'; -GRE2: 5' CTGCTGTACAGGATGTTCTAGC TACT 3'; -HBV: 5' CGTCAGCAAACACTTGGCACAGACC 3'; -Alb (F): 5' GATGGCAAACATACGCAAGGGATTTA 3'; -Alb (El): 5' TAAGAACAAACATTCCCTGTAT 3'; -Alb (E2): 5' CCAAGGCAAACACGTCCGGAAT 3'; -Oct Ig kappa: 5' TGAGGGTATGCAAATTATTAAGAAGC 3'; -Core: 5' TGCTGGGGACTTTCCACACCCTAA 3'; -NF1 site: 5' TAT TTTGGATTGAAGCCAATATGATAATGA 3'; -NFY site: 5' GGGGTAGGAACCAATGAAATGAAAGGTTA 3'; The last three oligonucleotides have been described by Raymondjean et al. (18) .
RESULTS
Cell type-specific giucocorticoid response is associated with binding sites for cell type-specific nuclear proteins in TAT gene GRUs We have used a transient expression assay to analyze the activity of the elements involved in rat TATgene giucocorticoid response in two cell lines. One, a rat hepatoma cell line, expresses the 7/47 gene while the other, a mouse fibroblast line, does not. The results are shown in Figure 1 . In hepatoma cells (H4H), 10 kbp of TAT gene 5' flanking region confer to a reporter CAT gene a level of giucocorticoid induction identical to that of the endogenous TAT gene (pTCIO). Deletion of the -10,095 to -3,337 region leads to a 70% decrease of the induction level (pTC3). Similar ratios of induction are obtained when the Herpes simplex virus tk promoter is substituted for the TAT gene promoter from position -1,295 to +3 (pKTIO and pKT3). In fibroblasts (L cells or an Ltk" subclone), neither 10 kbp nor 3 kbp of the TAT gene 5' flanking region produces a significant giucocorticoid response (pTCIO and pTC3). This cell typespecific giucocorticoid response is still observed with the tk promoter (pKTIO and pKT3). All the cell lines used contain a functional giucocorticoid receptor since CAT gene expression controlled by the mouse mammary tumor virus long terminal repeat is stimulated by glucocorticoids (data not shown).
The regions responsible for the effects observed were more precisely determined by the transfection of a series of constructs (8) . Figure 1 also shows that in hepatoma cells, a 289 bp fragment containing HSm (-2,630 to -2,342; pKT31) produces a giucocorticoid response similar to that of a 2 kbp fragment (-3,337 to -1,295; pKT3). Similarly, a 337 bp fragment containing HSV (-5,583 to -5,247; pCR51) enhances the HSEQ-driven giucocorticoid response to the level obtained with 9 or 10 kbp fragments of the TATgene 5' flanking region (pKTIO and pTCIO). These two fragments contain enough information (13); GRE2 is the sequence of the major GRBS of HSm 09). After normalization of the CAT activity with respect to the |3 galactosidase activity used as an internal control, the ratio of induction of CAT activity by dexamethasone (a giucocorticoid analog) was determined for each transfection (detailed experimental procedures are described in Grange et al.; 8) . The mean value of these independent ratios of induction is indicated ± the standard error of the mean. The number of independent experiments performed is indicated in brackets. N.D.: not done. Two clones of mouse L fibroblasts (AT-CC CCL 1.2 and ATCC CCL 1.3) were used without observing significant differences in the ratio of induction.
for cell type-specific glucocorticoid response since they are not functional in fibroblasts (pCR51). The sequences flanking the GRBS contribute to the activity of HSV in hepatoma cells (8) . This is also true for the HSIII region since an oligonucleotide corresponding to its major GRBS (GRE2; 9) is unable to produce a significant glucocorticoid response (pGR2 in Figure 1) .
To identify the putative elements involved in the cell typespecific glucocorticoid response we looked for binding sites of cell type-specific nuclear proteins by in vitro footprinting analysis with DNAase I (19) . Both strand of each GRU were analysed using crude nuclear extracts (CNE) prepared from both hepatoma cells and fibroblasts ( Figures nucleotides -2,440 to -2,414 and between nucleotides -5,322 to -5,291 which are protected only by the hepatoma cell CNE. The major difference is the presence in both GRUs of DNAase I hypersensitive sites specific to hepatoma cell CNE. In HSIII these sites are located at positions -2,431 and -2,428 in the lower and upper strands respectively ( Figure 2A ) and in HSV at positions -5,458, -5,375 and -5,312 in the lower strand and at -5,455, -5,372, -5,355 and -5,309 in the upper strand ( Figure 2B ). The nuclear proteins interacting with the TAT gene GRUs were analyzed by gel mobility shift assays (further designated gel shift assays; 17). We used five double-stranded synthetic oligonucleotides, termed si to s5, each covering a footprinted region of HSIII ( Figure 3 ). Oligonucleotides si, s2, and s3 give rise to similar retarded bands with both CNEs. In contrast, s4 binds (a) factor(s) only when incubated with hepatoma cell CNE. Oligonucleotide s5 binds (a) factor(s) presumably present in both extracts but in different relative amounts. The corresponding sequence includes a CACCC box homology, a motif described as the target sequence for TEF-2 (20) and maybe some other factors (21) . We have restricted our investigation to the characterization of the factors binding to oligonucleotides si to s4.
In both GRUs there are multiple binding sites for C/EBP as well as for other factors with similar binding specificity If si, s2 and s3 bind to similar protein(s), each one should compete with the others. When s3 is the labeled probe, si, s2 and s3 are all efficient competitors whatever the cell type of origin of the CNEs (Figure 4A and 4B). Identical results are obtained when si is the labeled probe (data not shown).
Oligonucleotides si, s2 and s3 do not share a common nucleotide sequence, but in all three it is possible to identify one of the two consensus binding sites (the CCAAT box and the enhancer core homology) of the nuclear protein C/EBP (22; see Figure 4C ). Two other well characterized nuclear proteins, NF1/CTF and NFY, bind to sequences containing the CCAAT motif (23 and references therein). Oligonucleotides corresponding to high affinity binding sites for each of these proteins were used as competitors of s3 in gel shift assays : 1) one corresponds to the SV40 enhancer core sequence, as a binding site for C/EBP (18, 24) ; 2) another to the CCAAT box of the rat albumin promoter, as a binding site for NFY (18, 23) ; and 3) a third to the CCAAT box of the adenovirus 2 origin of replication, as a binding site for NF1 (18, 25) . This analysis shows that out of these three binding sites, the SV40 enhancer core sequence is the most efficient competitor in both cell CNEs ( Figure 4A and 4B) thus excluding NFY and NF1 as the proteins responsible for the retarded bands.
C/EBP, the remaining putative candidate is expressed mostly in hepatocytes and adipocytes (26) . Its mRNA is not detectable in fibroblasts (27) ; thus in fibroblast CNE the protein(s) binding to oligonucleotides si, s2 and s3 must be different from C/EBP. figure 4A . Lane F represents the incubation without competitor. C: Oligonucleotides si, s2 and s3 each contain a sequence related to a described C/EBP binding site consensus (22) . The sequence of the relevant strand of each oligonucleotide is represented and the location of the region presenting significant homology with one of the consensuses for C/EBP binding sites is underlined. D: Differential heat stability of the DNA-binding activities present in the CNEs. Before incubation with labeled oligonucleotide s3, an aliquot of each CNE was treated for 10 min. at 90°C. After centrifugation, the activity remaining in the supernatant was tested in parallel with untreated extract. In each incubation the same volume of CNE was used corresponding to 6 fig and 10 fig of protein for respectively untreated hepatoma cell (H) and fibroblast (F) CNEs.
C/EBP is a thermoresistant protein (24) . Both CNEs were heated at 90°C for 10 min and the remaining DNA-binding activity was tested by gel shift assay. Figure 4D shows that half of the DNAbinding activity present in hepatoma cell CNE is thermoresistant.
In contrast most of the activity present in fibroblast CNE is heatsensitive. In conclusion one of the DNA-binding proteins responsible for the retarded bands obtained with si, s2 and s3 is present only in hepatoma cell CNE and is likely to be C/EBP. C/EBP indeed binds to the sequences included in the oligonucleotides si, s2 and s3: DNAase I footprinting performed with purified C/EBP on the HSm region shows a clear protection with boundaries identical to those obtained with both CNEs (Figures 5A and 2A) . In addition it reveals a fourth C/EBP binding site, located from position -2,388 to -2,360 ( Figure 2B ). Furthermore the two internal DNAase I hypersensitive sites specific to the hepatoma cell CNE (positions -5,372 and -5,355) are not obtained with purified C/EBP ( Figure 5B ). These differences result from the binding of other proteins (vide infra and data not shown).
In conclusion mere are four C/EBP binding sites in both HSUI and HSV. These binding sites are shared with other DNA-binding proteins with similar or different binding specificities.
The hepatoma cell-specific nuclear factor which binds oligonucleotide s4 possesses two binding sites in HSUI and four binding sites in HSV Figure 3 shows that oligonucleotide s4 gives rise to a retarded band specific to hepatoma cell CNE. Analysis of the DNAase I footprint obtained in the corresponding region reveals the presence, only with hepatoma cell CNE, of a DNAase I hypersensitive site on each strand (at positions -2,431 and -2,428 on the lower and upper strand respectively; Figure 2A ). We hypothesized that the same factors) was (were) responsible for the hepatoma cell-specific retarded band and the DNAase I hypersensitive sites. Since such hypersensitive sites are also obtained in the HSV region, we suspected that this factor(s) might also bind to that region. Figure 6A shows that competition with oligonucleotide s4 leads to the disappearance of the footprint extending from position -5,319 to -5,291 and of the four hepatoma cell-specific DNAase I hypersensitive sites; the resulting footprint pattern is similar to that obtained wim fibroblast CNE.
Comparison of the sequences of oligonucleotide s4 and of die regions including these 4 hypersensitive sites shows that they all possess a common seven nucleotide long motif (Figure 7 ). This motif is likely to be partly responsible for the recognition of these five sequences by die same hepatoma cell-specific factor(s) that will be referred to as the Hepatic Nuclear Factor n°5 (HNF5). The fixed positions of the DNAase I hypersensitive sites within the motif, anodier feature of HNF5 binding sites, indicates that HNF5 leaves two specific phosphodiester bonds (one on each strand) accessible to DNAase I.
Examination of die sequence of HSUI reveals another HNF5 motif located around position -2,480 ( Figure 7) . However, there are no DNAase I hypersensitive sites at the expected corresponding positions (Figure 2A ). Since this region is also a C/EBP binding site ( Figure 5A ), C/EBP (or factor(s) with similar binding specificity) could be responsible for nieir absence. To test this hypothesis we analyzed the effect of competition with oligonucleotide s3 which is a target site for C/EBP (Figure 4 ) but does not contain die HNF5 consensus motif (Figure 7) . Figure  6B shows that this competition with hepatoma cell CNE generates a DNAase I hypersensitive site at position -2,481 (compare lanes C, H and H+s3) i.e. at a location characteristic of HNF5 binding. HNF5 is indeed responsible for this hypersensitive site since simultaneous competition witii oligonucleotides s3 and s4 (an HNF5 binding site) leads to the control pattern (compare lanes C, H+s3 and H+s3+s4 in Figure 6B ). As expected from the cell-type specificity of HNF5, competition widi oligonucleotide s3 is sufficient to obtain die control pattern witfi fibroblast CNE (compare lanes F, F + s3 and C in Figure 6B) . A similar HNF5 and C/EBP binding site overlap is found twice in HSV around positions -5,355 and -5,370 ( Figures 5B and 6A ). In these regions however the DNAase I hypersensitive sites characteristic of HNF5 binding are visible (at least on one strand) wim uncompeted hepatoma cell CNE ( Figure 2B) . In conclusion there are two HNF5 binding sites in HSm and four HNF5 binding sites in HSV. Some of these sites overlap the binding sites of other factors including C/EBP.
HNF5 binding sites are also present in multiple regulatory sequences of other genes with liver-specific expression
The presence of HNF5 binding sites within two regulatory regions conferring liver cell type-specific gene expression prompted us to search for HNF5 binding sites in regulatory regions of other liver-specific genes. Sequences matching the consensus for HNF5 binding sites can indeed be found in many of these regulatory regions, and the characteristic DNAase I hypersensitive sites observed on some of the published footprints. Such putative binding sites are present, among others, in the following regulatory regions: 1) the hepatitis B virus enhancer [position 1196 to 1190, with a hypersensitive site (HSS) visible in Figure  2B in (28) To confirm some of these putative identifications we performed competition experiments with oligonucleotides corresponding to sites originating from the hepatitis B virus enhancer (HBV) and from the mouse albumin regulatory sequences (F, El and E2). We also tested oligonucleotides corresponding to 1) the octamer transcription factor binding site of the immunoglobulin kappa light chain gene (Oct Ig kappa; 34); it was selected because there is a striking similarity between the HNF5 consensus ( Figure 7 ) and the octamer sequence ATGCAAAT (34 and references therein); 2) the major GRBS of HSIII (GRE2; 9); it is a functional binding site for the glucocorticoid receptor when tested in gel shift experiments (data not shown); and 3) the oligonucleotide s4 mutated in the consensus sequence at the second and the seventh position (s4 mut). The results of these competitions (figure 8) lead to the following conclusions: 1) HNF5 binds to the four sites originating from liver-specific regulatory regions (the F site of the albumin promoter is a low-affinity site); 2) HNF5 is not one of the octamer transcription factors; 3) HNF5 is not the glucocorticoid receptor; and 4) the binding of HNF5 to its target sequence is abolished by the mutation of two bases located in the consensus sequence we have defined. 
DISCUSSION
We have analyzed the structure of two GRUs of the rat 7Mrgene. Each GRU (HSm and HSV) is composed of multiple binding sites of a limited number of DNA-binding proteins ( Figure 9 ). This modular organization appears to be a general feature of enhancer structure (4, 5) but the characteristic feature of these GRUs is the redundancy of the binding sites for three trans-acting factors.
One of these factors, the glucocorticoid receptor, has three binding sites in HSIII (9) and one in HSV (8) . The activity of this factor, expressed in most cell-types, is dependent upon the presence of the hormone (for reviews see 1, 2). It is the key transacting factor for the function of these GRUs because in the absence of hormone none of these GRUs activates gene expression (8) . The minimal requirement to produce a functional element conferring glucocorticoid responsivness is unclear. In some cases a GRBS alone has been reported to be sufficient (9, TATTTGCAATAGA  CATGGGGAAACTT  GCTGGGATTACAG  GGATTGCAGATGC  GCTGAGGTAAGAG  TATTTGTTTTGTG  TATTTGCTAAACT  TCATTGGCGAATT  TGATTGGTTAGTT  TCTGTGGTAAGCA  GGTGTGGAAAGTC   AATGTGGATATCC  TGTTTGCTGACGC   ATTTTGTAATGGG  TGGATGCTATAAC  CCTATGTTAAGTA  TATTAGGACATGT  ATGTTGAGTAAGA  CAGGTGGGCACAT 
35).
However similar experiments have shown that the presence of other transcription factor binding sites may be necessary (6, 36, 37). We have not obtained significant glucocorticoid stimulation using a GRBS originating from the HSm region (pGR2 in Figure 1 ). Sequences flanking the GRBS are necessary for the activity of both HSm (pKT31 in Figure 1 ) and HSV (8) . These two GRUs do not function in fibroblasts ( Figure 1 ) and their activity is extinguished in intertypic hepatoma-fibroblast hybrid cells (11) . Thus the flanking sequences must bind factors responsible for this cell-type specific activity. Two factors are likely candidates because they have multiple binding sites in each GRU. One, with four binding sites in each GRU, has the properties of C/EBP (22) . C/EBP is primarily expressed in hepatocytes and adipocytes, but not in fibroblasts (26, 27) . It recognizes the CC-AAT box and the enhancer core sequence. Since it does so with the same DNA binding domain (38 and references therein), this suggests that it recognizes common features in seemingly unrelated sequences. Analysis of 22 C/EBP binding sites allows the identification of a common eight nucleotide long motif related to the enhancer core sequence (Figure 10 ). This consensus can also be found in sites containing the CCAAT box homology suggesting the existence of a single class of C/EBP binding sites. In fibroblasts, Mercurio and Karin (39) have described a DNAbinding activity (AP-3) which recognizes sequences very similar to the consensus defined here (Figure 10 ). Thus the activity present in fibroblast CNE which binds C/EBP sites in the TA T gene GRUs (Figures 3 -4 , data not shown) could be related to AP-3. The heat-labile fraction of the activity detected in hepatoma cell CNE ( Figure 4D ) could also be related to AP-3. Other regulatory sequences are target sites for multiple DNA-binding proteins, for example the CCAATT boxes (23), the TPA responsive elements (40 and references therein), and the cAMP responsive elements (41) . The functional significance of this multiple recognition remains in most cases conjectural.
We have identified another cell-type specific DNA-binding activity which recognizes two sites in HSIH and four in HSV. This activity is present in hepatoma cell (lane s4, H in Figure  3 ) and in liver CNEs (data not shown), but neither in fibroblast Qane s4, F in Figure 3 ) nor in spleen, brain and heart CNEs (data not shown). Four liver-specific DNA-binding activities have been named HNF: HNF1 (42), also known as LF-B1 (43, 44) ; HNF2 (45) , also known as LF-A1 (43); HNF3 and HNF4 (46) . Since the consensus for the binding site of the factor we have identified ( Figure 7 ) is clearly different from the others, we have named it HNF5.
The nucleotide sequence features common to all HNF5 binding sites are likely to correspond to the recognized DNA motif. Indeed mutation of two bases therein abolishes HNF5 binding (Figure 8) . A characteristic feature of the interaction of HNF5 with its target sequence is revealed by DNAase I. This enzyme cleaves one phosphodiester bond on each strand, in the middle of the HNF5 recognition sequence, leaving a 3'-protruding 3 nucleotide-long stagger (Figure 7) . In vivo footprinting analysis shows that the pattern of DNA cleavage by DNAase I on occupied HNF5 binding sites is identical to that existing in vitro (G.R., T.G., J.R. and R.P.; in preparation). Usually DNAase I cleaves DNA on phosphates facing one another across the minor groove (47) . When DNA is set on a nucleosome, DNAase I cleaves the accessible phosphodiester bonds with a periodicity of 10 to 11 nucleotides on each strand generating a 3' protruding 2 nucleotide-long stagger (48) . Structural irregularities in the nucleosomal structure may lead to a modified cutting pattern at particular positions (49, 50) which could be due to a distortion of the DNA helix. By analogy, the DNA helix could be locally distorted upon HNF5 binding. Distortion of the target DNA may participate in the function of HNF5, for example by affecting the interaction of multiple factors binding to surrounding sequences.
In several instances, (once in HSIII, twice in HSV, once in the hepatitis B virus enhancer and once in the OTC enhancer) the HNF5 binding sites overlap C/EBP binding sites with a strict conservation of the overlap structure ( Figure 10 ). This suggests that, on these sites, there is a specific interaction between the two factors involving either simultaneous binding or mutual exclusion. The existence of overlaps between HNF5 and other factors binding sites may be a general property of HNF5. Indeed there is also an overlap between an HNF5 and a glucocorticoid receptor binding site (GRE3) in HSIQ. Another overlap, with an identical configuration, can be found in the mouse albumin enhancer at position -10,066 to -10,057, but in this case it is not known if the glucocorticoid receptor interacts with this region. Up to now we have identified only one HNF5 binding site, at position -5,317 to -5,302 in the TATgene, which seems not to be shared with other nuclear factors.
The exact role of C/EBP and HNF5 in the function of the TAT gene GRU is unclear. C/EBP is able to activate gene expression from several promoters (38 and references therein). One of the C/EBP binding sites identified here cooperatively enhances the activity of one of the GRBSs of HSm (37) . HNF5 is presumably a transcriptional activator because a multimerized HNF5 binding site activates gene expression in a cell type-specific way (data not shown). In vivo footprinting reveals that the interaction of HNF5 with its target sites in HSIII is dependent upon the presence of glucocorticoid hormone (G.R., T.G., J.R. and R.P.; in preparation). Together these data suggest that these factors participate positively in the glucocorticoid-dependent activation of 7M7"gene transcription. Their absence from fibroblasts could explain the inactivity of TAT gene GRUs in these cells.
Promoters and enhancers of liver-specific genes are made up of multiple binding sites for ubiquitous and liver-specific nuclear factors such as C/EBP and HNF1 to 4 (46 and references therein). We have observed that many regulatory elements of liver-specific genes contain HNF5 binding sites which are located close to those of one or more of the aforementioned liver-specific factors. These observations reinforce the notion that the liver-specific function of these regulatory elements is achieved through a complex interplay of several different liver-specific factors (16, 46) . Such participation of numerous trans-acting factors may allow the integration of multiple regulatory inputs by a single modular element. Indeed, the level of the active form of each trans-acting factor can be under discrete regulation, and variation in this level could affect the overall activity of the regulatory element. For example the intensity of the glucocorticoid stimulation exerted by the TAT gene GRUs could be modulated, not only by the level of activated glucocorticoid receptor, but also by the level of active C/EBP and HNF5 that could be under the control of various intracellular or extracellular stimuli.
Note added
A cDNA coding for an ubiquitous C/EBP like DNA-binding protein has just been isolated (57) .
